Moscow, Russia (PRWEB) February 12, 2013
Moscow, Russia January 31, 2013 -- Eastern Clinical Trials (ECT), a leading contract research organization (CRO) with operations in Russia and Central and Eastern Europe, announced today that it successfully passed with no major findings an inspection conducted by the European Medicines Agency (EMA).
The Inspection was conducted on 22-24 January 2013 at the site of Professor Sergey V. Orlov MD, PhD, of Saint Petersburg State Medical University, who is a principal investigator in a large registration oncology trial.
“We are very pleased to have passed the EMA Inspection” commented Dr. Svetlana Vodolazhskaya, Managing Director of Eastern Clinical Trials. “The Agency’s inspection results confirm that ECT's clinical research operations meet and often exceed international standards. We realize the importance of efficient operations that meet our client’s high requirements in drug development process and take great pride in both the quality of our work and in ECT's exceptional team of professionals.”
About Eastern Clinical Trials (ECT)(http://www.easterntrials.com)
Established in 2004, Eastern Clinical Trials (ECT) has grown from a local Moscow-based CRO to a trusted regional partner in clinical research with operations in Russia, Ukraine, Belarus, Georgia, Hungary and Slovakia. ECT provides a full spectrum of clinical trial services including project management, monitoring, study feasibility, regulatory submission and support, translation, safety reporting and warehousing.
Svetlana Vodolazhskaya, MD
Russia 119034 Moscow
Tel: + 7(925)5023189